Rabia AYDOĞAN BAYKARA, Ahmet OMMA, Erkan CÜRE, Ali Uğur USLU, Göksel TUZCU, Adem KÜÇÜK, Ayça TUZCU

The relationship of serum visfatin levels with clinical parameters, flow-mediated dilation, and carotid intima-media thickness in patients with ankylosing spondylitis

Background/aim: Atherosclerotic heart diseases can occur at an early age in patients with ankylosing spondylitis (AS). Flow-mediated dilation (FMD) and carotid intima-media thickness (cIMT) values are reliable markers for early detection of subclinical atherosclerosis in patients with AS. We aimed to investigate the relationship between visfatin levels and indirect markers of subclinical atherosclerosis and endothelial dysfunction in patients with AS. Materials and methods: Forty-two patients diagnosed with AS and 42 age, sex, and body mass index (BMI)-matched controls were included in the study. Visfatin levels, FMD, and cIMT were measured using appropriate methods. Results: Visfatin levels of the patients were significantly higher than controls (p < 0.001). FMD values in patients with AS were significantly lower (p = 0.007) whereas cIMT were significantly higher than the controls (p = 0.003). There was a negative relationship between FMD with visfatin levels (p = 0.004), BASDAI (p = 0.010), and BASFI (p = 0.007). There was a positive relationship between cIMT with visfatin (p = 0.005), BASDAI (p < 0.001), and BASFI (p < 0.001). There was a positive relationship between visfatin with BASDAI (p < 0.001), and BASFI (p < 0.001). Conclusion: Visfatin levels are increased and associated with impaired FMD and increased cIMT in patients with AS. Increased visfatin levels may be associated with subclinical atherosclerosis in AS.Key words: Visfatin, ankylosing spondylitis, flow-mediated dilation, carotid intima-media thickness, subclinical atherosclerosis

PDF

___

1. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Annals of the Rheumatic Diseases 2002; 61 (3): 8-18. doi: 10.1136/ard.61.suppl_3.iii8
2. Valente RL, Valente JM, De Castro GR, Zimmermann AF, Fialho SC et al. Subclinical atherosclerosis in ankylosing spondylitis: is there a role for inflammation? The Revista Brasileira de Reumatologia 2013; 53 (5): 377-381.
3. McCarey D, Sturrock RD. Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis. Clinical and Experimental Rheumatology 2009; 27 (55): 124-126.
4. Balciūnaitė A, Budrikis A, Rumbinaitė E, Sabaliauskienė J, Patamsytė V et al. Ankylosing spondyloarthritis resulting severe aortic insufficiency and aortitis: exacerbation of ankylosing spondyloarthritis and stenosis of the main left coronary artery after mechanical aortic valve implantation with cardiopulmonary bypass. Case Reports in Rheumatology 2020; 2020: 9538527. doi: 10.1155/2020/9538527
5. Ozkan Y. Cardiac involvement in ankylosing spondylitis. Journal of Clinical Medicine Research 2016; 8 (6): 427-430. doi: 10.14740/jocmr2488w
6. Hung YM, Chang WP, Wei JC, Chou P, Wang PY. Midlife ankylosing spondylitis increases the risk of cardiovascular diseases in males 5 years later: a national population-based study. Medicine (Baltimore) 2016; 95 (81): e3596. doi: 10.1097/ MD.0000000000003596
7. Cure E, Icli A, Uslu AU, Sakiz D, Cure MC et al. Atherogenic index of plasma: a useful marker for subclinical atherosclerosis in ankylosing spondylitis: AIP associate with cIMT in AS. Clinical Rheumatology 2018; 37 (5): 1273-1280. doi: 10.1007/ s10067-018-4027-0
8. Korkmaz H, Onalan O. Evaluation of endothelial dysfunction: flow-mediated dilation. Endothelium 2008; 15 (4): 157-163. doi: 10.1080/10623320802228872
9. Al-Qaisi M, Kharbanda RK, Mittal TK, Donald AE. Measurement of endothelial function and its clinical utility for cardiovascular risk. Vascular Health and Risk Management 2008; 4 (3): 647-652. doi: 10.2147/vhrm.s2769
10. Raitakari OT, Celermajer DS. Flow-mediated dilatation. The British Journal of Clinical Pharmacology 2000; 50 (5): 397-404. doi: 10.1046/j.1365-2125.2000.00277.x
11. Hug C, Lodish HF. Visfatin: a new adipokine. Science 2005; 307 (5708): 366-367. doi: 10.1126/science.1106933
12. Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mikhailidis DP. Visfatin/PBEF and atherosclerosis-related diseases. Current Vascular Pharmacology 2010; 8 (1): 12-28. doi: 10.2174/157016110790226679
13. Zheng LY, Xu X, Wan RH, Xia S, Lu J et al. Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes. Diabetology & Metabolic Syndrome 2019; 11: 60. doi: 10.1186/s13098-019-0455-5
14. Tang X, Chen M, Zhang W. Association between elevated visfatin and carotid atherosclerosis in patients with chronic kidney disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2013; 38 (69): 553-559. doi: 10.3969/j.issn.1672-7347.2013.06.002
15. Syrbe U, Callhoff J, Conrad K, Poddubnyy D, Haibel H et al. Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression. Arthritis and Rheumatology 2015; 67 (3): 678-685. doi: 10.1002/art.38968
16. Hulejova H, Kropackova T, Bubova K, Krystufkova O, Filkova M et al. Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study. Rheumatology International 2019; 39 (6): 1037-1043. doi: 10.1007/s00296-019-04301-z
17. Kadoglou NP, Sailer N, Moumtzouoglou A, Kapelouzou A, Tsanikidis H et al. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Experimental and Clinical Endocrinology and Diabetes 2010; 118 (2): 75-80. doi: 10.1055/s-0029-1237360
18. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007; 56 (4): 451-458. doi: 10.1016/j.metabol.2006.12.001
19. Song P, Fang Z, Wang H, Cai Y, Rahimi K et al. Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. The Lancet Global Health 2020; 8 (5): e721-e729. doi: 10.1016/ S2214-109X(20)30117-0
20. Eriksson JK, Jacobsson L, Bengtsson K, Askling J. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Annals of the Rheumatic Diseases 2017; 76 (2): 364-370. doi: 10.1136/ annrheumdis-2016-209315
21. Papadakis JA, Sidiropoulos PI, Karvounaris SA, Vrentzos GE, Spanakis EK et al. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity. Clinical and Experimental Rheumatology 2009; 27 (2): 292-298.
22. Tsai WC, Ou TT, Yen JH, Wu CC, Tung YC. Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study. PLoS One 2015; 10 (5): e0126347. doi: 10.1371/journal.pone.0126347
23. Genc H, Dogru T, Kara M, Tapan S, Ercin CN et al. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Annals of Hepatology 2013; 12 (4): 548-555.
24. Romacho T, Sánchez-Ferrer CF, Peiró C. Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators of Inflammation 2013; 2013: 946427. doi: 10.1155/2013/946427
25. Cakmak HA, Aslan S, Yalcin AA, Akturk IF, Yalcin B, et al. Relationship between serum visfatin levels and coronary slowflow phenomenon. Herz 2015; 40 (6): 921-928. doi: 10.1007/ s00059-015-4313-4
26. Zheng M, Lu N, Ren M, Chen H. Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction. BMC Cardiovascular Disorders 2020; 20 (1): 271. doi: 10.1186/s12872-020-01549-3
27. Stejskal D, Sigutova R, Svestak M, Vaclavik J, Kusnierova P et al. Measurement of novel adipokine visfatin in young patients with acute myocardial infarction. Clinical testing of a new ELISA. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2020; 164 (2): 138-140. doi: 10.5507/bp.2020.024
28. Miranda-Filloy JA, López-Mejias R, Genre F, Carnero-López B, Ochoa R et al. Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clinical and Experimental Rheumatology 2013; 31 (4): 538-545.
29. Rueda-Gotor J, Genre F, Corrales A, Blanco R, Fuentevilla P et al. Detection of high cardiovascular risk patients with ankylosing spondylitis based on the assessment of abdominal aortic calcium as compared to carotid ultrasound. Arthritis Research and Therapy 2018; 20 (1): 195. doi: 10.1186/s13075- 018-1684-y
30. Bodnár N, Kerekes G, Seres I, Paragh G, Kappelmayer J et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis. The Journal of Rheumatology 2011; 38 (4): 723-729. doi: 10.3899/jrheum.100668
31. Wang HH, Wang QF. Low vaspin levels are related to endothelial dysfunction in patients with ankylosing spondylitis. The Brazilian Journal of Medical and Biological Research 2016; 49 (7): e5231. doi: 10.1590/1414-431X20165231
32. Bessa SS, Hamdy SM, El-Sheikh RG. Serum visfatin as a non-traditional biomarker of endothelial dysfunction in chronic kidney disease: an Egyptian study. European Journal of Internal Medicine 2010; 21 (6): 530-535. doi: 10.1016/j. ejim.2010.09.011
33. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrology Dialysis Transplantation 2008; 23 (3): 959-965. doi: 10.1093/ndt/gfm727
34. Kucuk A, Uğur Uslu A, Icli A, Cure E, Arslan S et al. The LDL/HDL ratio and atherosclerosis in ankylosing spondylitis. Zeitschrift für Rheumatologie 2017; 76 (1): 58-63. doi: 10.1007/ s00393-016-0092-4
35. El-Shishtawy SH, Mosbah O, Sherif N, Metwaly A, Hanafy A et al. Association between serum visfatin and carotid atherosclerosis in diabetic and non-diabetic patients on maintenance hemodialysis. Electronic Physician 2016; 8 (2): 1966-1972. doi: 10.19082/1966
36. Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y et al. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clinical Endocrinology (Oxford) 2008; 69 (6): 878-884. doi: 10.1111/j.1365-2265.2008.03248.x
37. Ozgen M, Koca SS, Aksoy K, Dagli N, Ustundag B et al. Visfatin levels and intima-media thicknesses in rheumatic diseases. Clinical Rheumatology 2011; 30 (6): 757-763. doi: 10.1007/s10067-010-1649-2
38. Hsu CY, Huang PH, Chen TH, Chiang CH, Leu HB et al. Increased circulating visfatin is associated with progression of kidney disease in non-diabetic hypertensive patients. American Journal of Hypertension 2016; 29 (4): 528-536. doi: 10.1093/ajh/hpv132
39. Kanbay M, Yilmaz MI, Sonmez A, Turgut F, Saglam M et al. Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. The American Journal of Nephrology 2011; 33 (4): 298-304. doi: 10.1159/000324847
40. Matsui S, Kajikawa M, Hida E, Maruhashi T, Iwamoto Y et al. Optimal target level of low-density lipoprotein cholesterol for vascular function in statin naïve individuals. Scientific Reports 2017; 7 (1): 8422. doi: 10.1038/s41598-017-09043-1